SCHEMBL8238400

SCHEMBL8238400

CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCN(C)C(=O)N1C[C@H](OC(=O)c3ccc([N+](=O)[O-])cc3)C[C@H]1C(=O)N2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.37
▸ SMN1; SMN2 Q16637 5/20 0.36
▸ KCNJ1 P48048 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ PTPN1 P18031 2/20 0.33
▸ PTPN2 P17706 1/20 0.33
▸ GAA P10253 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ KMT2A Q03164 3/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ CHRM2 P08172 1/20 0.31
▸ CHRM4 P08173 1/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ CHRM3 P20309 1/20 0.31
▸ CCNA2 P20248 1/20 0.31
▸ CDK2 P24941 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2843889 1.00 POLB (0.37) POLBSMN1; SMN2KCNJ1KCNH2ALDH1A1
SCHEMBL2843887 1.00 POLB (0.37) POLBSMN1; SMN2KCNJ1KCNH2ALDH1A1
SCHEMBL6760115 1.00 POLB (0.37) POLBSMN1; SMN2KCNJ1KCNH2ALDH1A1
SCHEMBL14020643 0.98 POLB (0.38) POLBSMN1; SMN2KCNJ1KCNH2ALDH1A1
SCHEMBL16628787 0.91 POLB (0.40) POLBSMN1; SMN2ALDH1A1MAPTPTPN1
SCHEMBL16628788 0.91 POLB (0.40) POLBSMN1; SMN2ALDH1A1MAPTPTPN1
SCHEMBL8253707 0.90 ADRB3 (0.32) ALDH1A1ADRB3ADRA2BADRA2C
SCHEMBL12730845 0.87 SMN1; SMN2 (0.37) POLBSMN1; SMN2KCNJ1KCNH2ALDH1A1
SCHEMBL994827 0.87 KCNJ1 (0.33) POLBSMN1; SMN2KCNJ1KCNH2ALDH1A1
SCHEMBL994824 0.87 KCNJ1 (0.33) POLBSMN1; SMN2KCNJ1KCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919904-B1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS JANSSEN R & D IRELAND (IE) 2014-01-08 — — EP disclosed
US-8012939-B2 Macrocyclic inhibitors of hepatitis C virus Tibotec Pharmaceuticals Ltd. Co (IE) 2011-09-06 — — US disclosed
US-8012939-B2 Macrocyclic inhibitors of hepatitis C virus Tibotec Pharmaceuticals Ltd. Co (IE) 2011-09-06 — — US disclosed
US-20090281141-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS JANSSEN SCIENCES IRELAND UC (IE) 2009-11-12 — — US disclosed
US-20090281141-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS JANSSEN SCIENCES IRELAND UC (IE) 2009-11-12 — — US disclosed
WO-2007014921-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281141-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS CBR1, HCCS, CYP2B6 POLB 1970/4885SMN1; SMN2 4140/4885KCNJ1 3507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback